German construction sector still in recession, civil engineering only bright spot
Investing.com - Truist Securities maintained its Sell rating on Phreesia Inc. (NYSE:PHR) with a price target of $36.00, according to a research note released Friday. The healthcare software company, currently trading at $28.16, has shown strong momentum with a 21% return over the past six months, though InvestingPro analysis suggests the stock is currently fairly valued.
The firm updated its financial projections for the healthcare software company, raising its FY26/27 EBITDA estimates to $90 million and $110 million, respectively, compared to previous estimates of $88 million and $101 million.
Truist’s updated revenue forecasts for FY26/FY27 stand at $477 million and $539 million, slightly adjusted from prior estimates of $478 million and $539 million.
The analyst noted that these projections do not include any potential contribution from the possible AccessOne acquisition that Phreesia might complete.
The price target of $36, increased from $35 previously, is based on a multiple of 16x the firm’s CY2027 adjusted EBITDA estimate, compared to approximately 20x CY2026 adjusted EBITDA in its previous valuation approach.
In other recent news, Phreesia Inc . reported its first positive net income in the second quarter of fiscal year 2026, achieving earnings per share of $0.01, which exceeded the forecasted loss of $0.06. The company’s revenue grew by 15% year-over-year to $117.3 million, surpassing the projected $116.54 million. In addition, Phreesia announced a $160 million acquisition of AccessOne, expected to contribute approximately $35 million in annual revenue and $11 million in EBITDA once finalized in the latter half of fiscal year 2026.
Analysts have responded positively to these developments. Raymond James raised its price target for Phreesia to $33, citing the AccessOne acquisition. Canaccord Genuity increased its price target to $38, highlighting the expansion of Phreesia’s total addressable market to $24 billion. Needham also raised its target to $35, acknowledging the company’s strong quarterly results and effective expense management. Furthermore, DA Davidson initiated coverage with a Buy rating and a price target of $33, following Phreesia’s revenue and adjusted EBITDA results that exceeded expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.